Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis.

Shlomit Kfir-Erenfeld Nathalie Asherie Sigal Grisariu Batia Avni Eran Zimran Miri Assayag Tatyana Dubnikov Sharon Marjorie Pick Eyal Lebel Adir Shaulov Yael C Cohen Irit Avivi Cyrille J Cohen Polina Stepensky Moshe E E Gatt

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

BCMA-CART cells provide a first proof-of-concept that this therapy is safe enough and highly efficacious for the treatment of patients with advanced, RR AL.

Keyphrases

acute lymphoblastic leukemia
multiple myeloma
acute myeloid leukemia
stem cells
cell cycle arrest
cell death
cell proliferation
combination therapy
bone marrow
endoplasmic reticulum stress